Poster Presentation Details:
Title: Characteristics of Participants with Refractory Chronic Cough Enrolled in A Phase 2b Trial of BLU-5937
Session: Chronic Cough, Airway Diseases, and Methods
Date/Time:
Title: Efficacy in SOOTHE, A Phase 2b Trial of BLU-5937 In Refractory Chronic Cough, Was Not Dependant of Taste Disturbance Adverse Events
Session: Chronic Cough, Airway Diseases, and Methods
Date/Time:
Title: Improvements in Awake Cough Frequency in SOOTHE, A Phase 2b Trial of BLU-5937 in Refractory Chronic Cough
Session: Chronic Cough, Airway Diseases, and Methods
Date/Time:
ERS has announced that the abstracts and e-posters will be made available on the congress platform here on
About
Chronic cough is a cough lasting longer than eight weeks. When the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is referred to as RCC. It is estimated that there are approximately 9 million patients in
The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Forward-Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations, the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005029/en/
Chief Financial Officer
rbenamar@bellushealth.com
Media:
Solebury Trout
jdeutsch@soleburytrout.com
Source: